Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2025-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 26th meeting of the 5th Supervisory Board of 特一药业集团股份有限公司. It includes voting results on various agenda items such as the 2024 Supervisory Board Work Report, 2024 Financial Final Report, 2024 Profit Distribution Plan, 2024 Annual Report, Internal Control Self-Evaluation Report, and other related matters. The document repeatedly states that these reports are published separately on the 巨潮资讯网 (an information disclosure website) and that the resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full reports or detailed financial data but serves as an official announcement of the meeting's decisions and voting outcomes. The document length is only 1907 characters, which is short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE and the nature of the content, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of meeting resolutions and voting results but not the full Annual Report or other detailed reports themselves.
2025-04-25 Chinese
2024年度独立董事述职报告（李桂生）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2024 by an independent director of the company. It details the director's attendance at board and shareholder meetings, participation in board committees, supervision of company governance, and protection of shareholder rights. It is a narrative report on the director's activities and duties during the year rather than a financial report, audit report, or announcement. It does not contain financial statements or earnings data, nor is it a notice or announcement of voting results or management changes. This type of document fits best under Board/Management Information (MANG) as it relates to the activities and reports of a board member or senior management figure.
2025-04-25 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the 30th meeting of the 5th Board of Directors of 特一药业集团股份有限公司. It details the approval of various reports and proposals including the 2024 Board Work Report, General Manager Work Report, Financial Statements, Profit Distribution Plan, Annual Report, Internal Control Self-Evaluation Report, and other corporate governance matters. The document states that these reports are published or will be published on the same day or soon after, and that these resolutions will be submitted to the shareholders' meeting for approval. The document is a formal announcement of board meeting decisions rather than the reports themselves. It does not contain the full annual report or financial statements but references them as published elsewhere. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of board resolutions and related corporate governance matters, not the actual annual report or financial report.
2025-04-25 Chinese
关于拟续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (Daxin CPA Firm) as the auditor for the company's 2025 financial statements and internal control audit. It details the qualifications, independence, and past performance of the accounting firm, as well as the approval process by the board and audit committee. The document does not contain any actual financial statements or audit reports, but rather is a formal notice about the intention to renew the audit engagement, pending shareholder approval. The document length is about 3,053 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about audit firm reappointment and does not contain the audit report itself or detailed financial data.
2025-04-25 Chinese
关于2024年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2024 annual profit distribution plan of the company 特一药业集团股份有限公司. It includes details about the profit distribution proposal, cash dividend plans, and related financial figures for the fiscal year 2024. The document mentions the approval by the board and supervisory committee and states that the proposal will be submitted to the shareholders' meeting for approval. It also references the 2024 annual audit report as a backup document but does not contain the full audit report or detailed financial statements itself. The document length is 2484 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on dividend distribution plans and related shareholder information, which fits the definition of a Notice of Dividend Amount (DIV). Therefore, the appropriate classification is DIV with high confidence.
2025-04-25 Chinese
东莞证券股份有限公司关于特一药业集团股份有限公司2024年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2024 of a company, with detailed descriptions of internal control systems, governance, audit opinions, and compliance with regulatory requirements. It includes an audit opinion from an accounting firm on the effectiveness of internal controls as of December 31, 2024, and a verification opinion from the sponsoring securities firm. The document is about internal control evaluation and audit, not a full annual report or financial statement. It is a standalone audit-related report focusing on internal control evaluation and audit opinions, which fits the definition of an Audit Report / Information (AR). The document length is 6689 characters, which is sufficient to be the report itself, not just an announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-04-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.